NEW YORK, January 30, 2017 /PRNewswire/
Stock-Callers.com takes note of the performances of these four Generic Drugs stocks: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Lannett Co. Inc. (NYSE: LCI). PCI Synthesis' issued an annual list of trends that will affect the emerging Generic Drugs market in 2017, according to which, the capacity for early stage programs could be tight, the CRO/CMO sectors will witness more consolidation, big pharma consolidation could also pick up, small biotech companies could innovate more and there could be significant uncertainty around the FDA and drug pricing during 2017. Learn more about these stocks by downloading their comprehensive and free reports at:
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s shares finished Friday's session 0.14% higher at $13.97 with a total trading volume of 1.11 million shares. The stock has gained 3.94% in the previous three months. The Company's shares are trading above their 200-day moving average by 1.30%. Moreover, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 31.81.
On January 26th, 2017, Ironwood Pharmaceuticals and Allergan PLC announced that the US Food and Drug Administration (FDA) has approved a 72 mcg dose of LINZESS (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients. The newly approved dose will provide physicians with dosing flexibility based on individual presentation or tolerability, in treating the large and heterogenous population of adult CIC patients. The new dose is expected to be available in Q1 2017. Since the launch of LINZESS in December of 2012, nearly 1.5 million unique patients have filled nearly 7 million prescriptions, according to IMS Health data. IRWD complete research report is just a click away and free at:
Shares in Parsippany, New Jersey-based The Medicines Co. ended the day 0.20% lower at $34.92 with a total trading volume of 979,872 shares. The stock has advanced 2.89% on an YTD basis. The Company's shares are trading 2.07% below their 50-day moving average. Moreover, shares of Medicines Co., which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 45.47.
On January 25th, 2017, Medicines Co. announced that full safety and efficacy data from the ORION-1 Phase-2 study of inclisiran, with six- to nine-month follow-up for all patients in the study, will be presented at the American College of Cardiology's 66th Annual Scientific Session, to be held March 17th-19th, 2017, in Washington DC. The complimentary report on MDCO can be downloaded at:
South San Francisco, California-based Rigel Pharmaceuticals Inc.'s stock rose 1.02%, closing the session at $1.98 with a total trading volume of 379,308 shares. The Company's shares are trading 21.24% below their 50-day moving average. Shares of the Company, which engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 29.16.
On January 16th, 2017, Rigel Pharma announced that on January 03rd, 2017, and January 16th, 2017, the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 214,000 shares of common stock to four new employees. The stock options vest as follows: certain of the shares of common stock subject to the award vest in equal monthly installments over a two period subject to the achievement of one or more performance conditions and certain of the shares of common stock subject to the award vest in equal monthly installments over a four-year period, with one-fourth of the shares subject to the award vesting on the first anniversary of the vesting commencement date. Sign up for your complimentary research report on RIGL at:
On Friday, shares in Philadelphia, Pennsylvania-based Lannett Co. Inc. finished the session 2.35% higher at $19.60. A total volume of 659,713 shares was traded. The stock is trading below its 50-day moving average by 12.37%. Furthermore, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 39.66.
On January 25th, 2017, Lannett announced that it will report financial results for Q2 FY17 on February 01st, 2017, after the market closes. Lannett's management will host a conference call that same afternoon at 4:30 p.m. ET to review the Company's performance and answer questions. Get free access to your research report on LCI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA